Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial Juan A. Garcia-Velasco, M.D., Guillermo Quea, M.D., Manuel Piró, M.D., Mercedes Mayoral, M.D., María Ruiz, R.N., Mónica Toribio, R.N., Antonio Requena, M.D. Fertility and Sterility Volume 92, Issue 1, Pages 222-225 (July 2009) DOI: 10.1016/j.fertnstert.2008.04.042 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Serum E2 values of egg donors taking letrozole after egg retrieval (dark green) versus placebo (light green) throughout the luteal phase. ∗P<.001. Fertility and Sterility 2009 92, 222-225DOI: (10.1016/j.fertnstert.2008.04.042) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions
Figure 2 Serum LH concentrations in donors taking letrozole (dark pink) or placebo (light pink) for 5 days after ovum pick-up. The LH starts to behave differently on day hCG+7, when a significant increase is detected at the time of E2 decrease in this particular group, and continuous throughout the luteal phase. However, due to the high serum E2 concentrations described in the control group, their serum LH levels are still significantly lower. ∗P<.001. Fertility and Sterility 2009 92, 222-225DOI: (10.1016/j.fertnstert.2008.04.042) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions